A meta-analysis of convalescent plasma in the treatment of patients with severe coronavirus disease 2019

YANG Cheng; FENG Chunlu; LIU Min; TUO Lin; GENG Xiaoxia; YANG Xingxiang

doi:10.7619/jcmp.20220999

Journal of Clinical Medicine in Practice > 2022 > 26(11): 6-11. > DOI: 10.7619/jcmp.20220999

YANG Cheng, FENG Chunlu, LIU Min, TUO Lin, GENG Xiaoxia, YANG Xingxiang. A meta-analysis of convalescent plasma in the treatment of patients with severe coronavirus disease 2019[J]. Journal of Clinical Medicine in Practice, 2022, 26(11): 6-11. DOI: 10.7619/jcmp.20220999

Citation:

PDF (2744 KB)

A meta-analysis of convalescent plasma in the treatment of patients with severe coronavirus disease 2019

YANG Cheng^{1, 2},
FENG Chunlu^{1, 2},
LIU Min^{2, 3},
TUO Lin²,
GENG Xiaoxia^{1, 2},
YANG Xingxiang^{1, 2, 3, ,}

1.
School of Medicine of University of Electronic Science and Technology of China, Chengdu, Sichuan, 610054
2.
Department of Infection, Sichuan Provincial People′s Hospital, Chengdu, Sichuan, 610072
3.
Chengdu Medical College, Chengdu, Sichuan, 610500

More Information

Received Date: March 28, 2022
Available Online: May 16, 2022

Graphical Abstract

Abstract

Abstract

Objective
To evaluate the effectiveness and safety of convalescent plasma in treatment of patients with severe coronavirus disease 2019(COVID-19) by meta-analysis.
Methods
Databases such as EMBASE, PubMed, Web of Science, Cochrane Library, China National Knowledge Infrastructure(CNKI) and Chinese Biomedical Literature Database were searched to collect randomized controlled trials (RCTs) about convalescent plasma therapy for severe COVID-19, and the search deadline was December 1, 2021. The efficacy evaluation indexes included 28 d or 30 d mortality and discharge rate, and the safety evaluation index was the incidence of adverse events. A meta-analysis was performed by using RevMan 5.3 software.
Results
A total of 9 RCTs including 3 461 patients were enrolled in this meta-analysis, and the results showed that there were no significant differences in the 28 d or 30 d all-cause mortality (RR=0.94, 95%CI, 0.84 to 1.05, P=0.27), 28 d or 30 d discharge rate (RR=1.06, 95%CI, 0.95 to 1.19, P=0.28) and incidence of adverse events (RR=1.16, 95%CI, 0.71 to 1.88, P=0.55)between routine regimen and convalescent plasma.
Conclusion
meta-analysis of this study suggests that the convalescent plasma is safe in the treatment of patients with severe COVID-19, but it has no significant improvement in short-term mortality and discharge rate.
- convalescent plasma,
- coronavirus disease 2019,
- systematic analysis,
- all-cause mortality,
- databases,
- safety,
- effectiveness

FullText(HTML)

References (22)

References

[1]	LI C, REN L Z. Recent progress on the diagnosis of 2019 novel coronavirus[J]. Transbound Emerg Dis, 2020, 67(4): 1485-1491. doi: 10.1111/tbed.13620
[2]	BURNOUF T, SEGHATCHIAN J. Ebola virus convalescent blood products: where we are now and where we may need to go[J]. Transfus Apher Sci, 2014, 51(2): 120-125. doi: 10.1016/j.transci.2014.10.003
[3]	RAJAM G, SAMPSON J, CARLONE G M, et al. An augmented passive immune therapy to treat fulminant bacterial infections[J]. Recent Pat Antiinfect Drug Discov, 2010, 5(2): 157-167. doi: 10.2174/157489110791233496
[4]	DEVASENAPATHY N, YE Z K, LOEB M, et al. Efficacy and safety of convalescent plasma for severe COVID-19 based on evidence in other severe respiratory viral infections: a systematic review and meta-analysis[J]. CMAJ, 2020, 192(27): E745-E755. doi: 10.1503/cmaj.200642
[5]	ROJAS M, RODRÍGUEZ Y, MONSALVED M, et al. Convalescent plasma in Covid-19: possible mechanisms of action[J]. Autoimmun Rev, 2020, 19(7): 102554. doi: 10.1016/j.autrev.2020.102554
[6]	朱鑫方, 王苑, 杜丹心, 等. 康复者恢复期血浆在病毒性疾病治疗中的研究进展[J]. 临床输血与检验, 2020, 22(4): 337-342. doi: 10.3969/j.issn.1671-2587.2020.04.001
[7]	中华人民共和国卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第八版修正版)[EB/OL]. (2021-04-05)[2022-03-25]. http://www.nhc.gov.cn/yzygj/s7653p/202104/7de0b3837c8b4606a0594aeb0105232b/files/f192ac6e5567469db4f0a8691ca18907.pdf.
[8]	SIMONOVICHV A, BURGOS PRATXL D, SCIBONA P, et al. A randomized trial of convalescent plasma in covid-19 severe pneumonia[J]. N Engl J Med, 2021, 384(7): 619-629. doi: 10.1056/NEJMoa2031304
[9]	LI L, ZHANG W, HU Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: arandomized clinical trial[J]. JAMA, 2020, 324(5): 460-470. doi: 10.1001/jama.2020.10044
[10]	AGARWAL A, MUKHERJEE A, KUMAR G, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase Ⅱ multicentre randomised controlled trial (PLACID Trial)[J]. BMJ, 2020, 371: m3939.
[11]	WRITING COMMITTEEFORTHE REMAP-CAP INVESTIGATORS, ESTCOURTL J, TURGEONA F, et al. Effect of convalescent plasma on organ support-free days in critically ill patients with COVID-19: arandomized clinical trial[J]. JAMA, 2021, 326(17): 1690-1702.
[12]	ALQAHTANI M, ABDULRAHMAN A, ALMADANI A, et al. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease[J]. Sci Rep, 2021, 11(1): 9927. doi: 10.1038/s41598-021-89444-5
[13]	BAR K J, SHAW P A, CHOI G H, et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia[J]. J Clin Invest, 2021, 131(24): e155114. doi: 10.1172/JCI155114
[14]	SEKINE L, ARNS B, FABROB R, et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial[J]. Eur Respir J, 2022, 59(2): 2101471. doi: 10.1183/13993003.01471-2021
[15]	RAY Y, PAULS R, BANDOPADHYAY P, et al. A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19[J]. Nat Commun, 2022, 13(1): 383. doi: 10.1038/s41467-022-28064-7
[16]	O'DONNELLM R, GRINSZTEJN B, CUMMINGSM J, et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19[J]. J Clin Invest, 2021, 131(13): e150646. doi: 10.1172/JCI150646
[17]	GROUP R C. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial[J]. Lancet, 2021, 397(10289): 2049-2059.
[18]	JOYNER M J, BRUNO K A, KLASSEN S A, et al. Safety update: COVID-19 convalescent plasma in 20, 000 hospitalized patients[J]. Mayo Clin Proc, 2020, 95(9): 1888-1897. doi: 10.1016/j.mayocp.2020.06.028
[19]	LIBSTER R, MARC G P, WAPPNER D, et al. Early high-titer plasma therapy to prevent severe covid-19 in older adults[J]. N Engl J Med, 2021, 384(7): 610-618. doi: 10.1056/NEJMoa2033700
[20]	SALAZAR E, CHRISTENSENP A, GRAVISSE A, et al. Treatment of coronavirus disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality[J]. Am J Pathol, 2020, 190(11): 2290-2303. doi: 10.1016/j.ajpath.2020.08.001
[21]	JOYNERM J, SENEFELDJ W, KLASSENS A, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience[J]. medRxiv, 2020, DOI: 10.1101/2020.08.12.20169359.
[22]	DUAN K, LIU B D, LI C S, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients[J]. Proc Natl Acad Sci USA, 2020, 117(17): 9490-9496. doi: 10.1073/pnas.2004168117

[1]	WU Nan, ZHENG Miaomiao, WANG Xinzhe, ZHU Xiang, TANG Hao. Research progress of protein arginine methyltransferase regulating bone formation and bone healing[J]. Journal of Clinical Medicine in Practice, 2024, 28(5): 126-129, 134. DOI: 10.7619/jcmp.20233520
[2]	HUANG Wei, WANG Xu, SHEN Zhimei, CUI Fei. Research progress on mechanism of action of stromal cell derived factor-1 in osteoporosis[J]. Journal of Clinical Medicine in Practice, 2022, 26(21): 144-148. DOI: 10.7619/jcmp.20222400
[3]	SHEN Qin, ZHU Hong, CHEN Luyuan. Effects of LncRNA NEF on differentiation and expression of related proteins of osteoblasts and osteoclasts[J]. Journal of Clinical Medicine in Practice, 2022, 26(20): 10-15, 22. DOI: 10.7619/jcmp.20220630
[4]	DONG Hui, YU Hang, WANG Yongxiang. Research progress in role and mechanism of circular RNA in osteoporosis[J]. Journal of Clinical Medicine in Practice, 2021, 25(4): 111-115. DOI: 10.7619/jcmp.20210167
[5]	LI Hongda, WU Hualong, WU Shuangshi, ZHAO Jiwei, SUN Hao, HU Le, WANG Yongxiang. Research on screening of serum differential proteins in patients with osteoporosis by iTRAQ technology[J]. Journal of Clinical Medicine in Practice, 2020, 24(21): 97-101. DOI: 10.7619/jcmp.202021028
[6]	ZHANG hai-yan, LIU qi, YANG jun-hai. Attachment and proliferation of alveolar bone cells to diseased root surfaces treated with platelet- poor plasma and demineralization in vitro[J]. Journal of Clinical Medicine in Practice, 2011, (21): 33-36. DOI: 10.3969/j.issn.1672-2353.2011.21.011
[7]	ZHEN Peng-fei, DONG Zhan, WANG Jie-guo, LOU Yao. Thyrocalcitonin regulates the cbfa1mRNA expression of osteoblasts via signal pathway of ERK-MAPK[J]. Journal of Clinical Medicine in Practice, 2009, (7): 35-38. DOI: 10.3969/j.issn.1672-2353.2009.07.009
[9]	ZHAO Ji-dong, ZHU Jian-zhong, MIAO Zong-lin, QIAN Han-guang, PENG Wei. THE EXPERIMENT STUDY OF THE DIFFERENTIATION OF BONE MARROW MESENCHMAL STEM CELLS TO EXPRESS THE PHENOTYPE OF CHONDROCYTE LINEAGEBY TRANSFORMING GROWTH FACTOR-β3 IN VITRO[J]. Journal of Clinical Medicine in Practice, 2005, (11): 45-48. DOI: 10.3969/j.issn.1672-2353.2005.11.013
[10]	EXPERIMENTAL STUDY OF OSTEOBLASTS FROM HUMAN BONE MARROW COCULTURE WITH THE NANOMETER MATERIAL[J]. Journal of Clinical Medicine in Practice, 2003, (3): 212-214. DOI: 10.3969/j.issn.1672-2353.2003.03.008

Cited By

Get Citation

PDF

XML

Article views (205) PDF downloads (19)

Turn off MathJax

Article Contents

Abstract

References

A meta-analysis of convalescent plasma in the treatment of patients with severe coronavirus disease 2019

Abstract

References

Related Articles

Catalog

A meta-analysis of convalescent plasma in the treatment of patients with severe coronavirus disease 2019

Abstract

References

Related Articles

Catalog

Export File

Citation

Format

Content